Allergic reaction triggers FDA hold on Pluristem trial; shares plunge
This article was originally published in Scrip
Executive Summary
Panicked investors drove shares of Pluristem Therapeutics down as low as 26% on 4 June after the company revealed the US FDA had slapped a clinical hold on the Israeli firm's Phase II trial of its experimental placenta-based cell therapy, PLX-PAD, under investigation for intermittent claudication (IC) after one of the 74 enrolled patients was hospitalized after experiencing a serious allergic reaction.